Last updated 2026-07-20
- Raised $34M Series B led by New Enterprise Associates, Oct 2017
- Raised $10M Seed round led by Lundbeckfond Ventures, Oct 2013
- Raised $16M Seed round led by New Enterprise Associates, Apr 2013
Portfolio
0
in our dataset
Rounds participated
0
Rounds led
0
Rounds' value
—
total disclosed, rounds participated
Stages
—
About
Cydan is an orphan drug accelerator that identifies and de-risks programs with therapeutic and commercial potential. The company evaluates experimental new therapies and advances those with the highest potential to be disease-modifying treatments. Cydan's goal is to launch new companies focused on developing promising therapies for rare genetic diseases with high unmet medical need.
Portfolio
No portfolio companies in this dataset yet.
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
Identifiers & details
| Founded | 2013-4 |
|---|
Radar intelligence
Patents
| EPO | 1 |
|---|
Publications (Crossref)
| Works | 2 |
|---|